Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 107

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 107
---
, dealers or agents by counsel that we will name in the applicable prospectus supplement.

<div align='center'>EXPERTS</div>

The financial statements as
of December 31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have
been so incorporated in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said
firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory
paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements as
of December 31, 2023, and for each of the two years in the period then ended, incorporated by reference into this prospectus and in the
registration statement, have been so incorporated in reliance on a report of Forvis Mazars LLP (then-named Mazars LLP), an independent
registered accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements
for the year ended December 31, 2023 contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis Mazars LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>ENFORCEMENT OF JUDGMENTS</div>

We are a public limited company
incorporated under the laws of England and Wales. Certain of our directors and executive officers and experts named in this prospectus
reside outside of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside
the United States. As a result, it may be difficult for an investor to serve process on us or our directors and executive officers or
to compel any of them to appear in Court in the United States or to enforce judgments obtained in U.S. courts against them or us, including
judgments based on civil liability provisions of the securities laws of the United States. In addition, awards of punitive damages in
actions brought in the United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the
U.S. securities laws would be considered punitive in the United Kingdom if it does not seek to compensate the claimant